Evidence from market analysis and biodiversity science indicates that the decline in output from the pharmaceutical sector since the mid-1980s can be attributed to a move away from natural product exploration ("bioprospecting") in favor of genomics and synthetic chemistry, indeed claims about the value of undiscovered pharmaceuticals may not provide enough incentive for companies in free markets to search for them because of the high cost of development; meanwhile, natural products have a long history of supporting significant economic and health innovation.